Robert Christenson

List of Publications by Year
in descending order

236 papers	14,987 citations	24978 57 h-index	19690 117 g-index
240 all docs	240 docs citations	240 times ranked	13007 citing authors

#	Article	IF	Citations
1	Assessing Phlebotomy Device Preference and Specimen Quality in an Oncology Outpatient Clinic. journal of applied laboratory medicine, The, 2022, 7, 532-540.	0.6	3
2	Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. American Journal of Kidney Diseases, 2022, 79, 383-392.	2.1	15
3	Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction. American Journal of Emergency Medicine, 2022, 56, 323-324.	0.7	1
4	Glycated Albumin for the Diagnosis of Diabetes in US Adults. Clinical Chemistry, 2022, 68, 413-421.	1.5	18
5	Glycated Albumin and Risk of Mortality in the US Adult Population. Clinical Chemistry, 2022, 68, 422-430.	1.5	15
6	Multiple Cardiac Biomarker Testing Among Patients With Acute Dyspnea From the ICON-RELOADED Study. Journal of Cardiac Failure, 2022, 28, 226-233.	0.7	4
7	Glycated Albumin in Pristine and Non-Pristine Stored Samples in the National Health and Nutrition Examination Survey (NHANES) 1999â€“2004. journal of applied laboratory medicine, The, 2022, 7, 916-922.	0.6	5
8	The performance of glycated albumin as a biomarker of hyperglycemia and cardiometabolic risk in children and adolescents in the United States. Pediatric Diabetes, 2022, 23, 237-247.	1.2	1
9	Associations of Glycated Albumin and HbA1c with Chronic Kidney Disease in US Adults. journal of applied laboratory medicine, The, 2022, 7, 842-853.	0.6	2
10	Pathology Trainees Gain Clinical Pathology Experience as Lab Consultants Through Auditing Myeloid Mutation Panel Send-Out Tests: Hitting Two Birds With One Stone?. Archives of Pathology and Laboratory Medicine, 2022, 146, 1286-1290.	1.2	1
11	Glycated albumin and HbA1c as markers of lower extremity disease in US adults with and without diabetes. Diabetes Research and Clinical Practice, 2022, 184, 109212.	1.1	3
12	Prediction of Incident Heart Failure in CKD: The CRIC Study. Kidney International Reports, 2022, 7, 708-719.	0.4	5
13	Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic. Journal of Oncology, 2022, 2022, 1-8.	0.6	0
14	Lower diagnostic accuracy of hs-cTnI in patients with prior coronary artery bypass grafting. International Journal of Cardiology, 2022, 354, 1-6.	0.8	4
15	Point-of-Care: Roadmap for Analytical Characterization and Validation of a High-Sensitivity Cardiac Troponin I Assay in Plasma and Whole Blood Matrices. journal of applied laboratory medicine, The, 2022, 7, 971-988.	0.6	11
16	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, , .	0.6	0
17	The Relationship of Falls With Achieved 25-Hydroxyvitamin D Levels From Vitamin D Supplementation: The STURDY Trial. Journal of the Endocrine Society, 2022, 6, bvac065.	0.1	6
18	Finding acute coronary syndrome with serial troponin testing for rapid assessment of cardiac ischemic symptoms (FAST-TRAC): a study protocol. Clinical and Experimental Emergency Medicine, 2022, 9, 140-145.	0.5	4

#	Article	IF	Citations
19	The Effects of Four Doses of Vitamin D Supplements on Falls in Older Adults. Annals of Internal Medicine, 2021, 174, 145-156.	2.0	47
20	Outpatient versus observation/inpatient management of emergency department patients rapidly ruled-out for acute myocardial infarction: Findings from the HIGH-US study. American Heart Journal, 2021, 231, 6-17.	1.2	2
21	Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome. Clinical Research in Cardiology, 2021, 110, 1353-1368.	1.5	8
22	Nourin-Dependent miR-137 and miR-106b: Novel Early Inflammatory Diagnostic Biomarkers for Unstable Angina Patients. Biomolecules, 2021, 11, 368.	1.8	9
23	Risk Factors Associated With SARS-CoV-2 Seropositivity Among US Health Care Personnel. JAMA Network Open, 2021, 4, e211283.	2.8	112
24	Nourin-Associated miRNAs: Novel Inflammatory Monitoring Markers for Cyclocreatine Phosphate Therapy in Heart Failure. International Journal of Molecular Sciences, 2021, 22, 3575.	1.8	4
25	Performance of 4 Automated SARS-CoV-2 Serology Assay Platforms in a Large Cohort Including Susceptible COVID-19â€“Negative and COVID-19â€“Positive Patients. journal of applied laboratory medicine, The, 2021, 6, 942-952.	0.6	6
26	Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort. Circulation, 2021, 143, 1659-1672.	1.6	39
27	Validation of COVID-19 serologic tests and large scale screening of asymptomatic healthcare workers. Clinical Biochemistry, 2021, 90, 23-27.	0.8	10
28	Nourin-Dependent miR-137 and miR-106b: Novel Biomarkers for Early Diagnosis of Myocardial Ischemia in Coronary Artery Disease Patients. Diagnostics, 2021, 11, 703.	1.3	8
29	Prognostic Utility of a Modified HEART Score When Different Troponin Cut Points Are Used. Critical Pathways in Cardiology, 2021, 20, 134-139.	0.2	2
30	Health economic evaluations of medical tests: Translating laboratory information into value â€“ A case study example. Annals of Clinical Biochemistry, 2021, , 000456322110138.	0.8	1
31	Effects of Diet and Sodium Reduction on Cardiac Injury, Strain, and Inflammation. Journal of the American College of Cardiology, 2021, 77, 2625-2634.	1.2	34
32	Prediction of Incident Atrial Fibrillation in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1015-1024.	2.2	7
33	Response by Allen et al to Letter Regarding Article, â€œDiagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohortâ€• Circulation, 2021, 144, e285-e286.	1.6	1
34	Monocyte chemoattractant protein-1 is not predictive of cardiac events in patients with non-low-risk chest pain. Emergency Medicine Journal, 2021, , emermed-2021-211266.	0.4	0
35	A value proposition for natriuretic peptide measurement in the assessment of patients with suspected acute heart failure. Clinica Chimica Acta, 2020, 500, 98-103.	0.5	9
36	Healthy diet reduces markers of cardiac injury and inflammation regardless of macronutrients: Results from the OmniHeart trial. International Journal of Cardiology, 2020, 299, 282-288.	0.8	18

#	Article	IF	Citations
37	Pivotal findings for a high-sensitivity cardiac troponin assay: Results of the HIGH-US study. Clinical Biochemistry, 2020, 78, 32-39.	0.8	12
38	Relation of Biomarkers of Cardiac Injury, Stress, and Fibrosis With Cardiac Mechanics in Patients â‰¥ 65 Years of Age. American Journal of Cardiology, 2020, 136, 156-163.	0.7	6
39	Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD. Kidney International Reports, 2020, 5, 1052-1060.	0.4	11
40	Associations Between Dietary Patterns and Subclinical Cardiac Injury. Annals of Internal Medicine, 2020, 172, 786-794.	2.0	18
41	Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction. American Journal of Emergency Medicine, 2020, 46, 170-175.	0.7	5
42	Optimal Detection of Acute Myocardial Injury and Infarction with Cardiac Troponin: Beyond the 99th Percentile, into the High-Sensitivity Era. Current Cardiology Reports, 2020, 22, 101.	1.3	9
43	Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assayâ€™s Limit of Detection?. Clinical Chemistry, 2020, 66, 1146-1149.	1.5	7
44	Special Collection on the Value of Laboratory Medicine. journal of applied laboratory medicine, The, 2020, 5, 841-843.	0.6	1
45	Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction. Circulation, 2020, 142, 1532-1544.	1.6	31
46	Echocardiographic assessment of insulinâ€like growth factor binding proteinâ€7 and early identification of acute heart failure. ESC Heart Failure, 2020, 7, 1664-1675.	1.4	19
47	The utility of risk scores when evaluating for acute myocardial infarction using high-sensitivity cardiac troponin I. American Heart Journal, 2020, 227, 1-8.	1.2	7
48	Analytical and clinical characterization of a novel high-sensitivity cardiac troponin assay in a United States population. Clinical Biochemistry, 2020, 83, 28-36.	0.8	5
49	Evidence-based laboratory medicine. , 2020, , 265-288.		0
50	Out of the Darkness, Into the Light: Value of SARS-CoV-2 Antibody Testing in Populations to Benefit Public Health and in Individuals for Peace of Mind. journal of applied laboratory medicine, The, 2020, 5, 1101-1106.	0.6	0
51	A Multicenter Evaluation of a Nongel Mechanical Separator Plasma Blood Collection Tube for Testing of Selected Therapeutic Drugs. journal of applied laboratory medicine, The, 2020, 5, 671-685.	0.6	5
52	Performance of Novel High-Sensitivity Cardiac Troponin I Assays for 0/1-Hour and 0/2- to 3-Hour Evaluations for Acute Myocardial Infarction: Results From the HIGH-US Study. Annals of Emergency Medicine, 2020, 76, 1-13.	0.3	49
53	Predictive Performance of Traumatic Brain Injury Biomarkers in High-Risk Elderly Patients. journal of applied laboratory medicine, The, 2020, 5, 91-100.	0.6	14
54	Sex-Specific 99th Percentile Upper Reference Limits for High Sensitivity Cardiac Troponin Assays Derived Using a Universal Sample Bank. Clinical Chemistry, 2020, 66, 434-444.	1.5	80

#	Article	IF	Citations
55	Myocardial Infarction Can Be Safely Excluded by Highâ€sensitivity Troponin I Testing 3 Hours After Emergency Department Presentation. Academic Emergency Medicine, 2020, 27, 671-680.	0.8	10
56	Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea. JACC: Heart Failure, 2020, 8, 415-422.	1.9	13
57	Donor-Derived Cell-Free DNA Testing in Solid Organ Transplantation: A Value Proposition. journal of applied laboratory medicine, The, 2020, 5, 993-1004.	0.6	18
58	Copeptin to rule out myocardial infarction in Blacks versus Caucasians. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 395-403.	0.4	6
59	Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I. Journal of the American College of Cardiology, 2019, 74, 271-282.	1.2	75
60	ElecsysÂ® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	0.8	60
61	Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition. Clinica Chimica Acta, 2019, 495, 481-486.	0.5	23
62	Compensated Interferometry Measures of CYFRA 21â€“1 Improve Diagnosis of Lung Cancer. ACS Combinatorial Science, 2019, 21, 465-472.	3.8	26
63	Trial design for assessing analytical and clinical performance of high-sensitivity cardiac troponin I assays in the United States: The HIGH-US study. Contemporary Clinical Trials Communications, 2019, 14, 100337.	0.5	13
64	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. Journal of the American College of Cardiology, 2019, 73, 1059-1077.	1.2	103
65	Associations of microvascular dysfunction with cardiovascular outcomes: The cardiac, endothelial function and arterial stiffness in ESRD (CERES) cohort. Hemodialysis International, 2019, 23, 58-68.	0.4	10
66	Symptoms Predictive of Acute Myocardial Infarction in the Troponin Era: Analysis From the TRAPID-AMI Study. Critical Pathways in Cardiology, 2019, 18, 10-15.	0.2	7
67	Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. Aids, 2019, 33, 229-236.	1.0	18
68	Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. International Journal of Cardiology, 2019, 276, 261-267.	0.8	25
69	â€œMalignantâ€•Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multiâ€Ethnic Study of) Tj ETQq1 1 0.784314 rgBT /Ove	1.8	23
70	Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Digestive Diseases and Sciences, 2018, 63, 665-675.	1.1	23
71	Novel mediators of statin effects on plaque in HIV. Aids, 2018, 32, 867-876.	1.0	9
72	Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 105-110.	0.9	14

#	Article	IF	Citations
73	Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry, 2018, 64, 645-655.	1.5	327
74	N-Terminal Proâ€“B-Type Natriuretic Peptide in the Emergency Department. Journal of the American College of Cardiology, 2018, 71, 1191-1200.	1.2	136
75	Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Translational Research, 2018, 195, 25-47.	2.2	43
76	Celebrating AACC's 70th Anniversary: 1948 to 2018â€”A Thank-you Note to the Founders. journal of applied laboratory medicine, The, 2018, 2, 469-470.	0.6	0
77	The Passing of a Great Humanist. journal of applied laboratory medicine, The, 2018, 2, 814-815.	0.6	0
78	William Edward Highsmith. journal of applied laboratory medicine, The, 2018, 3, 336-337.	0.6	0
79	P1â€285: MULTICENTER EVALUATION OF THE ANALYTICAL CHARACTERISTICS OF THE ELECSYS^{Â®} TOTALâ€TAU CEREBROSPINAL FLUID (CSF) AND ELECSYS^{Â®} PHOSPHOâ€TAU (181P) CSF IMMUNOASSAYS. Alzheimer's and Dementia, 2018, 14, P393.	0.4	0
80	Provocative biomarker stress test: stress-delta N-terminal pro-B type natriuretic peptide. Open Heart, 2018, 5, e000847.	0.9	5
81	1-h Evaluation for Acute Myocardial Infarction Using the Generation 5 Cardiac Troponin T Assay. Journal of the American College of Cardiology, 2018, 72, 2677-2679.	1.2	4
82	Evaluation of the Elecsys Syphilis Immunoassay for Detection of Syphilis in Populations at Risk of Disease in the US and Argentina. journal of applied laboratory medicine, The, 2018, 3, 89-99.	0.6	1
83	Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. Journal of the American College of Cardiology, 2018, 72, 3246-3254.	1.2	51
84	Rationale and design of the Study To Understand Fall Reduction and Vitamin D in You (STURDY): A randomized clinical trial of Vitamin D supplement doses for the prevention of falls in older adults. Contemporary Clinical Trials, 2018, 73, 111-122.	0.8	22
85	High-sensitivity troponin T in preterm infants with a hemodynamically significant patent ductus arteriosus. Journal of Perinatology, 2018, 38, 1483-1489.	0.9	14
86	Differentiating type 1 and 2 acute myocardial infarctions using the N-terminal pro B-type natriuretic peptide/cardiac troponin T ratio. American Journal of Emergency Medicine, 2018, 36, 1849-1854.	0.7	10
87	Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurology, The, 2018, 17, 782-789.	4.9	330
88	Validation of high-sensitivity performance for a United States Food and Drug Administration cleared cardiac troponin I assay. Clinical Biochemistry, 2018, 56, 4-10.	0.8	28
89	Ultrarapid Rule-out for Acute Myocardial Infarction Using the Generation 5 Cardiac Troponin T Assay: Results From the REACTION-US Study. Annals of Emergency Medicine, 2018, 72, 654-664.	0.3	20
90	High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure. Circulation, 2017, 135, 1494-1505.	1.6	143

#	Article	IF	Citations
91	Serial Sampling of High-Sensitivity Cardiac Troponin T May Not Be Required for Prediction of Acute Myocardial Infarction Diagnosis in Chest Pain Patients with Highly Abnormal Concentrations at Presentation. Clinical Chemistry, 2017, 63, 542-551.	1.5	33
92	Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort. Clinical Chemistry, 2017, 63, 980-989.	1.5	42
93	High sensitivity cardiac troponin T in patients not having an acute coronary syndrome: results from the TRAPID-AMI study. Biomarkers, 2017, 22, 709-714.	0.9	9
94	Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	1.6	23
95	Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal proâ€“B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department. American Heart Journal, 2017, 192, 26-37.	1.2	13
96	The troponin decision-point dilemma: The 99th percentile solution â€œdo the best you can [with cardiac troponin] until you know better. Then when you know better, do better.â€•Maya Angelou, poet, dancer, producer, playwright, director, author. American Heart Journal, 2017, 190, 132-134.	1.2	1
97	Necessity of hospitalization and stress testing in low risk chest pain patients. American Journal of Emergency Medicine, 2017, 35, 274-280.	0.7	3
98	Multicenter evaluation of analytical characteristics of the ElecsysÂ® Periostin immunoassay. Clinical Biochemistry, 2017, 50, 139-144.	0.8	27
99	An Automated Assay for Growth Differentiation Factor 15. journal of applied laboratory medicine, The, 2017, 1, 510-521.	0.6	35
100	Are Heart Failure Management Recommendations and Guidelines Followed in Laboratory Medicine in Europe and North America? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study. journal of applied laboratory medicine, The, 2017, 1, 483-493.	0.6	5
101	Creation of a Universal Sample Bank for Determining the 99th Percentile for Cardiac Troponin Assays. journal of applied laboratory medicine, The, 2017, 1, 711-719.	0.6	20
102	Comparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study. journal of applied laboratory medicine, The, 2017, 1, 544-561.	0.6	24
103	Myocardial Ischemia on Exercise Stress Echocardiography Testing Is Not Associated with Changes in Troponin T Concentrations. journal of applied laboratory medicine, The, 2017, 1, 532-543.	0.6	7
104	The Era for High-Sensitivity Cardiac Troponin Has Begun in the US (Finally). journal of applied laboratory medicine, The, 2017, 2, 1-3.	0.6	16
105	Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review. journal of applied laboratory medicine, The, 2016, 1, 214-229.	0.6	38
106	The Use of Very Low Concentrations of Highâ€sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Blood Test. Academic Emergency Medicine, 2016, 23, 1004-1013.	0.8	64
107	Galectinâ€3 and Risk of Heart Failure and Death in Blacks and Whites. Journal of the American Heart Association, 2016, 5, .	1.6	25
108	Effect of type and amount of dietary carbohydrate on biomarkers of glucose homeostasis and C reactive protein in overweight or obese adults: results from the OmniCarb trial. BMJ Open Diabetes Research and Care, 2016, 4, e000276.	1.2	8

#	Article	IF	Citations
109	Cardiorespiratory Fitness and Highly Sensitive Cardiac Troponin Levels in a Preventive Medicine Cohort. Journal of the American Heart Association, 2016, 5, .	1.6	1
110	Leveraging the real value of laboratory medicine with the value proposition. Clinica Chimica Acta, 2016, 462, 183-186.	0.5	50
111	Impact of moderate physical activity on the longitudinal trajectory of a cardiac specific biomarker of injury: Results from a randomized pilot study of exercise intervention. American Heart Journal, 2016, 179, 151-156.	1.2	24
112	Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Communityâ€Dwelling Population. Journal of the American Heart Association, 2016, 5, .	1.6	67
113	Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. Aids, 2016, 30, 2205-2214.	1.0	25
114	Critical appraisal in the practice of laboratory medicine. Annals of Clinical Biochemistry, 2016, 53, 222-232.	0.8	1
115	Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Annals of Emergency Medicine, 2016, 68, 76-87.e4.	0.3	294
116	Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T â€" Sub-analysis from the TRAPID-AMI study. International Journal of Cardiology, 2016, 209, 26-33.	0.8	101
117	Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers andÂDimethylarginines. Clinical Gastroenterology and Hepatology, 2016, 14, 624-632.e2.	2.4	24
118	Measurements Matter. journal of applied laboratory medicine, The, 2016, 1, 1-4.	0.6	1
119	The standards for reporting diagnostic accuracy studies 2015 update: is there a missing link to the triumvirate?. Annals of Translational Medicine, 2016, 4, 44.	0.7	5
120	Older Adults, â€œMalignantâ€•Left VentricularÂHypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes toÂIdentify the Differential Risk of New-OnsetÂReduced Versus PreservedÂEjectionÂFraction Heart Failure. JACC: Heart Failure, 2015, 3, 445-455.	1.9	56
121	Evaluation of standardization capability of current cardiac troponin I assays by a correlation study: results of an IFCC pilot project. Clinical Chemistry and Laboratory Medicine, 2015, 53, 677-90.	1.4	33
122	Diagnostic performance of cardiac Troponin I for early rule-in and rule-out of acute myocardial infarction: Results of a prospective multicenter trial. Clinical Biochemistry, 2015, 48, 254-259.	0.8	24
123	Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clinical Biochemistry, 2015, 48, 292-296.	0.8	28
124	Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study. Journal of the American Heart Association, 2015, 4, .	1.6	41
125	Evolving Role of Galectin-3 as a CardiacÂBiomarker. JACC: Heart Failure, 2015, 3, 253-256.	1.9	11
126	Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practicesâ„¢ systematic review. Clinical Biochemistry, 2015, 48, 204-212.	0.8	20

#	Article	IF	Citations
127	Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Childâ€“Turcotteâ€“Pugh Class C Cirrhosis and Renal Dysfunction. Digestive Diseases and Sciences, 2015, 60, 3491-3494.	1.1	1
128	Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. Clinical Chemistry, 2015, 61, 1524-1531.	1.5	34
129	Cardiac biomarkers â€" A short biography. Clinical Biochemistry, 2015, 48, 197-200.	0.8	17
130	Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trial. Clinical Biochemistry, 2015, 48, 260-267.	0.8	21
131	High-Sensitivity Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and Risk of Incident Heart Failure in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 946-956.	3.0	101
132	Defining the Path Forward: Guidance for Laboratory Medicine Guidelines. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2015, 26, 158-67.	0.7	4
133	Multisite evaluation of a monoclonal IMMULITE erythropoietin immunoassay. Clinical Biochemistry, 2014, 47, 216-219.	0.8	1
134	Troponin I and NT-proBNP and the Association of Systolic BloodÂPressure With Outcomes in Incident Hemodialysis Patients: TheÂChoices for Healthy Outcomes in Caring for ESRDÂ(CHOICE)ÂStudy. American Journal of Kidney Diseases, 2014, 64, 443-451.	2.1	16
135	Searching for evidence: a guide to finding the evidence in laboratory medicine. Annals of Clinical Biochemistry, 2014, 51, 326-334.	0.8	3
136	Cardiac biomarkers in heart failure. Clinical Biochemistry, 2014, 47, 327-337.	0.8	48
137	Heart failure biomarkers at point-of-care: current utilization and future potential. Expert Review of Molecular Diagnostics, 2014, 14, 185-197.	1.5	13
138	Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay. Journal of the American College of Cardiology, 2014, 63, 1441-1448.	1.2	303
139	Prognostic implications of creatine kinaseâ€“MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. American Heart Journal, 2014, 168, 503-511.e2.	1.2	24
140	10. Natriuretic peptides. , 2014, , 181-194.		0
141	Copeptin Helps in the Early Detection of Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 150-160.	1.2	153
142	Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care. Clinical Biochemistry, 2013, 46, 969-978.	0.8	45
143	Long-Term Trajectory of Two Unique Cardiac Biomarkers and Subsequent Left Ventricular Structural Pathology and Risk of Incident Heart Failure in Community-Dwelling Older Adults at Low Baseline Risk. JACC: Heart Failure, 2013, 1, 353-360.	1.9	38
144	Amino Terminal Proâ€“B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy. Stroke, 2013, 44, 714-719.	1.0	101

#	Article	IF	Citations
145	Ask the right question: a critical step for practicing evidence-based laboratory medicine. Annals of Clinical Biochemistry, 2013, 50, 306-314.	0.8	11
146	Characteristics of cardiac troponin measurements. Coronary Artery Disease, 2013, 24, 698-704.	0.3	5
147	The Role of Cardiac Biomarkers in the Diagnosis and Management of Patients Presenting with Suspected Acute Coronary Syndrome. Annals of Laboratory Medicine, 2013, 33, 309-318.	1.2	26
148	Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers, 2012, 17, 706-713.	0.9	45
149	Influence of Population Selection on the 99th Percentile Reference Value for Cardiac Troponin Assays. Clinical Chemistry, 2012, 58, 219-225.	1.5	230
150	Point: Put Simply, Standardization of Cardiac Troponin I Is Complicated. Clinical Chemistry, 2012, 58, 165-168.	1.5	24
151	Preamble: â€˜Evidence in Action: The Laboratory Medicine Best Practice Initiativeâ€™. Clinical Biochemistry, 2012, 45, 977-978.	0.8	2
152	Effectiveness of practices to reduce blood culture contamination: A Laboratory Medicine Best Practices systematic review and meta-analysis. Clinical Biochemistry, 2012, 45, 999-1011.	0.8	112
153	Effectiveness of barcoding for reducing patient specimen and laboratory testing identification errors: A Laboratory Medicine Best Practices systematic review and meta-analysis. Clinical Biochemistry, 2012, 45, 988-998.	0.8	53
154	Effectiveness of automated notification and customer service call centers for timely and accurate reporting of critical values: A laboratory medicine best practices systematic review and meta-analysis. Clinical Biochemistry, 2012, 45, 979-987.	0.8	34
155	Physical Activity, Change in Biomarkers of Myocardial Stress and Injury, and Subsequent Heart Failure Risk in Older Adults. Journal of the American College of Cardiology, 2012, 60, 2539-2547.	1.2	106
156	Methodological and Analytic Considerations for Blood Biomarkers. Progress in Cardiovascular Diseases, 2012, 55, 25-33.	1.6	22
157	Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen, and Alpha-Fetoprotein on the Dimension VistaÂ® System. Clinical Biochemistry, 2011, 44, 1128-1136.	0.8	7
158	Sensitive and high sensitivity next generation cardiac troponin assays: more than just a name. Pathology, 2011, 43, 213-219.	0.3	23
159	Predictive Value of Depressive Symptoms and B-Type Natriuretic Peptide for New-Onset Heart Failure and Mortality. American Journal of Cardiology, 2011, 107, 723-729.	0.7	51
160	Prognostic Utility of ST2 in Patients with Acute Dyspnea and Preserved Left Ventricular Ejection Fraction. Clinical Chemistry, 2011, 57, 874-882.	1.5	81
161	Roadmap for Harmonization of Clinical Laboratory Measurement Procedures. Clinical Chemistry, 2011, 57, 1108-1117.	1.5	192
162	Laboratory Medicine Best Practices: Systematic Evidence Review and Evaluation Methods for Quality Improvement. Clinical Chemistry, 2011, 57, 816-825.	1.5	53

#	Article	IF	Citations
163	Multi-center determination of galectin-3 assay performance characteristics:. Clinical Biochemistry, 2010, 43, 683-690.	0.8	640
164	Post-discharge changes in NT-proBNP and quality of life after acute dyspnea hospitalization as predictors of one-year outcomes. Clinical Biochemistry, 2010, 43, 1405-1410.	0.8	12
165	Association of Serial Measures of Cardiac Troponin T Using a Sensitive Assay With Incident Heart Failure and Cardiovascular Mortality in Older Adults. JAMA - Journal of the American Medical Association, 2010, 304, 2494.	3.8	610
166	Development of a candidate secondary reference procedure (immunoassay based measurement) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 preliminary validation. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1603-10.	1.4	11
167	Commentary. Clinical Chemistry, 2010, 56, 706-707.	1.5	0
168	Impact of Increased Body Mass Index on Accuracy of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP for Diagnosis of Decompensated Heart Failure and Prediction of All-Cause Mortality. Clinical Chemistry, 2010, 56, 633-641.	1.5	35
169	Dynamic Cardiovascular Risk Assessment in Elderly People. Journal of the American College of Cardiology, 2010, 55, 441-450.	1.2	113
170	Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. Journal of the American College of Cardiology, 2010, 55, 2062-2076.	1.2	467
171	Standardisation of cardiac troponin I measurement: past and present. Pathology, 2010, 42, 402-408.	0.3	68
172	Lack of Diagnostic and Prognostic Utility of Circulating Plasma Myeloperoxidase Concentrations in Patients Presenting with Dyspnea. Clinical Chemistry, 2009, 55, 59-67.	1.5	27
173	Cardiac point of care testing: A focused review of current National Academy of Clinical Biochemistry guidelines and measurement platforms. Clinical Biochemistry, 2009, 42, 150-157.	0.8	53
174	Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure. Clinical Chemistry, 2009, 55, 2098-2112.	1.5	187
175	Cardiac Markers: A Chest Pain Center Focus. , 2009, , 91-113.		0
176	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure. Clinical Biochemistry, 2008, 41, 222-226.	0.8	24
177	Special section: Utilization of B-type natriuretic peptide and N-terminal B-type natriuretic peptide in laboratory medicine. Clinical Biochemistry, 2008, 41, 207.	0.8	0
178	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. Clinical Biochemistry, 2008, 41, 210-221.	0.8	61
179	Amino-Terminal Proâ€“B-Type Natriuretic Peptide: Analytic Considerations. American Journal of Cardiology, 2008, 101, S9-S15.	0.7	66
180	Standardization of troponin I measurements: an update. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1501-6.	1.4	47

#	Article	IF	Citations
181	What is the value of B-type natriuretic peptide testing for diagnosis, prognosis or monitoring of critically ill adult patients in intensive care?. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1524-32.	1.4	16
182	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Clinical Chemistry, 2007, 53, 552-574.	1.5	383
183	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. Clinical Chemistry, 2007, 53, 2086-2096.	1.5	239
184	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Utilization of Biochemical Markers in Acute Coronary Syndromes and Heart Failure. Clinical Chemistry, 2007, 53, 545-546.	1.5	23
185	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. Clinical Chemistry, 2007, 53, 547-551.	1.5	188
186	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. Circulation, 2007, 115, e352-5.	1.6	211
187	Evidence-based laboratory medicine - a guide for critical evaluation of in vitro laboratory testing. Annals of Clinical Biochemistry, 2007, 44, 111-130.	0.8	45
188	Impact of Renal Disease on Natriuretic Peptide Testing for Diagnosing Decompensated Heart Failure and Predicting Mortality. Clinical Chemistry, 2007, 53, 1511-1519.	1.5	93
189	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Utilization of Biochemical Markers in Acute Coronary Syndromes and Heart Failure. Circulation, 2007, 115, .	1.6	3
190	The Characteristics and Prognostic Importance of NT-ProBNP Concentrations in Critically Ill Patients. American Journal of Medicine, 2007, 120, 1071-1077.	0.6	38
191	Stability of B-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the Biosite Triage or Beckman-Coulter Access systems. Clinica Chimica Acta, 2007, 384, 176-178.	0.5	13
192	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure. Circulation, 2007, 116, e95-8.	1.6	79
193	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulation, 2007, 115, e356-75.	1.6	348
194	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. Circulation, 2007, 116, e99-109.	1.6	234
195	Biomarkers of Myocardial Necrosis. , 2006, , 3-25.		5
196	B-Type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. American Heart Journal, 2006, 152, 1071-1076.	1.2	135
197	Toward Standardization of Cardiac Troponin I Measurements Part II: Assessing Commutability of Candidate Reference Materials and Harmonization of Cardiac Troponin I Assays. Clinical Chemistry, 2006, 52, 1685-1692.	1.5	84
198	Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements. MedGenMed: Medscape General Medicine, 2006, 8, 62.	0.2	0

#	Article	IF	Citations
199	Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clinical Chemistry, 2005, 51, 810-824.	1.5	385
200	Quality Specifications for B-Type Natriuretic Peptide Assays. Clinical Chemistry, 2005, 51, 486-493.	1.5	181
201	Validation of the 99th Percentile Cutoff Independent of Assay Imprecision (CV) for Cardiac Troponin Monitoring for Ruling Out Myocardial Infarction. Clinical Chemistry, 2005, 51, 2198-2200.	1.5	123
202	Evaluation of Imprecision for Cardiac Troponin Assays at Low-Range Concentrations. Clinical Chemistry, 2004, 50, 327-332.	1.5	342
203	StratusÂ® CS cardiac troponin I method: performance characteristics including imprecision at low concentrations. Clinical Biochemistry, 2004, 37, 679-683.	0.8	46
204	Standardization of immunoassays for measurement of myoglobin in serum. Phase I: Evaluation of candidate secondary reference materials. Clinica Chimica Acta, 2004, 341, 65-72.	0.5	20
205	B-type natriuretic peptide: physiologic role and assay characteristics. Heart Failure Reviews, 2003, 8, 315-320.	1.7	26
206	Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. Journal of the American College of Cardiology, 2003, 41, 371-380.	1.2	67
207	Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clinica Chimica Acta, 2003, 338, 107-115.	0.5	276
208	Clinical performance characteristics of a new photometric lithium assay: a multicenter study. Clinica Chimica Acta, 2003, 327, 157-164.	0.5	19
209	Case Definitions for Acute Coronary Heart Disease in Epidemiology and Clinical Research Studies. Circulation, 2003, 108, 2543-2549.	1.6	719
210	Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers. , 2003, , 59-86.		0
211	A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation. American Heart Journal, 2002, 144, 834-839.	1.2	172
212	Cardiac markers of acute coronary syndromes: is there a case for point-of-care testing?. Clinical Biochemistry, 2002, 35, 13-27.	0.8	56
213	Improving the Care of Patients with Non-ST-elevation Acute Coronary Syndromes in the Emergency Department: The CRUSADE Initiative. Academic Emergency Medicine, 2002, 9, 1146-1155.	0.8	137
214	Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. Journal of the American College of Cardiology, 2001, 37, 9-18.	1.2	235
215	Standardization of Cardiac Troponin I Assays: Round Robin of Ten Candidate Reference Materials. Clinical Chemistry, 2001, 47, 431-437.	1.5	106
216	Performance characteristics of a revised cardiac Troponin I assay for the Opusâ„¢ plus immunoassay system. Clinical Biochemistry, 2001, 34, 579-582.	0.8	7

#	Article	IF	Citations
217	Analysis of the Albumin Cobalt Binding (ACBâ„¢) Test as an Adjunct to Cardiac Troponin I for the Early Detection of Acute Myocardial Infarction. Cardiovascular Toxicology, 2001, 1, 147-152.	1.1	49
218	Determination of the Falloff Constant (k_f) from Modeling Biochemical Marker Release: A New Variable for Discriminating Therapies. Cardiovascular Toxicology, 2001, 1, 171-176.	1.1	2
219	Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarctionâ—â—A complete list of the TAMI Study Group appears in J Am Coll Cardiol 1992;19:482â€“489.. American Journal of Cardiology, 2000, 85, 543-547.	0.7	57
220	Prodromal unstable angina in acute myocardial infarction: Prognostic value of short- and long-term outcome and predictor of infarct size. American Heart Journal, 2000, 140, 126-133.	1.2	58
221	Multicenter Clinical and Analytical Evaluation of the AxSYM Troponin-I Immunoassay to Assist in the Diagnosis of Myocardial Infarction. Clinical Chemistry, 1999, 45, 206-212.	1.5	89
222	Simultaneous Rapid Measurement of Whole Blood Myoglobin, Creatine Kinase MB, and Cardiac Troponin I by the Triage Cardiac Panel for Detection of Myocardial Infarction. Clinical Chemistry, 1999, 45, 199-205.	1.5	171
223	Evidence based approach to practice guides and decision thresholds for cardiac markers. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 90-102.	0.6	21
224	Multisite Study of a Second Generation Whole Blood Rapid Assay for Cardiac Troponin T. Annals of Clinical Biochemistry, 1999, 36, 438-446.	0.8	4
225	Value of Serial Troponin T Measures for Early and Late Risk Stratification in Patients With Acute Coronary Syndromes. Circulation, 1998, 98, 1853-1859.	1.6	259
226	Two of the authors of the article cited in the two preceding letters respond:. Clinical Chemistry, 1998, 44, 1787-1789.	1.5	0
227	Biochemical markers of the acute coronary syndromes. Clinical Chemistry, 1998, 44, 1855-1864.	1.5	121
228	Communications: Gentamicin Concentrations in Toadfish and Goldfish Serum. Journal of Aquatic Animal Health, 1997, 9, 211-215.	0.6	9
229	Multicenter study of Abbott AxSYMÂ® Digoxin II assay and comparison with 6 methods for susceptibility to digoxin-like immunoreactive factors. Clinical Chemistry, 1997, 43, 1635-1640.	1.5	22
230	All About Albumin: Biochemistry, Genetics, and Medical Applications. Theodore Peters, Jr. San Diego, CA: Academic Press, 1996, 432 pp, $85.00. ISBN 0-12-552110-3. Clinical Chemistry, 1997, 43, 2014a-2015.	1.5	25
231	Reply to Vipin D. Shah. Journal of Clinical Laboratory Analysis, 1996, 10, 55-56.	0.9	0
232	Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia. New England Journal of Medicine, 1996, 335, 1333-1342.	13.9	1,042
233	Thyroid function testing evaluated on three immunoassay systems. Journal of Clinical Laboratory Analysis, 1995, 9, 178-183.	0.9	6
234	Specificity of an immunochemical reagent for quantifying the isoforms of creatine kinase-MB. Journal of Clinical Laboratory Analysis, 1993, 7, 220-224.	0.9	8

#	Article	IF	Citations
235	Temporal Creatine Kinase Curves in Acute Myocardial Infarction:Implications of a Good Empiric Fit With the Log-Normal Function. American Journal of Clinical Pathology, 1993, 100, 293-298.	0.4	39
236	Lecithin cholesterol acyltransferase in human cerebrospinal fluid: reduced level in patients with multiple sclerosis and evidence of direct synthesis in the brain. International Journal of Clinical and Laboratory Research, 1992, 22, 169-172.	1.0	21